Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 2 2Phase 2/3 1Phase 1/2 1

Status

Active not recruiting 2Recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 1Lymphoid 1

Conditions

Primary Myelofibrosis 10Myeloproliferative Disorders 8Leukemia, Myeloid, Acute 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Myelodysplastic Syndromes 6Thrombocythemia, Essential 5Leukemia, Myelogenous, Chronic, BCR-ABL Positive 5Neoplasms 4Multiple Myeloma 4Leukemia 4Recurrence 3Polycythemia Vera 3Pancreatic Neoplasms 3Lymphoma, T-Cell 3Lymphoma, Non-Hodgkin 3Leukemia, Myelomonocytic, Chronic 3Myelodysplastic-Myeloproliferative Diseases 2Leukemia, Myeloid, Chronic-Phase 2Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 2Leukemia, Lymphocytic, Chronic, B-Cell 2Hodgkin Disease 2Colorectal Neoplasms 2Uveal Melanoma 1Triple Negative Breast Neoplasms 1Thrombocytosis 1Prostatic Neoplasms 1Neoplasm, Residual 1Neoplasm Metastasis 1Myeloproliferative Syndrome, Transient 1Mycosis Fungoides 1

Interventions

Cyclophosphamide 41fludarabine 31Dexamethasone 27venetoclax 25Cytarabine 22Rituximab 16pembrolizumab 15fludarabine phosphate 14Filgrastim 12Etoposide 12Lenalidomide 11Vincristine 10Gemcitabine 10Azacitidine 10pomalidomide 9Interleukin-2 9Granulocyte Colony-Stimulating Factor 9Doxorubicin 9Calcium Dobesilate 9carfilzomib 8Topotecan 8Nivolumab 8Methotrexate 8Everolimus 8Decitabine 8Bortezomib 8Melphalan 7Cisplatin 7Vorinostat 6Injections 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × Recurrence × ruxolitinib × Clear all
NCT05010005 2026-04-09

A Study of Ruxolitinib and Duvelisib in People With Lymphoma

Memorial Sloan Kettering Cancer Center

Phase 1 Recruiting
70 enrolled
LymphoidOther hematologic neoplasm

Recurrence, Leukemia, Prolymphocytic, T-Cell, Lymphoma, T-Cell, Leukemia, Large Granular Lymphocytic

NCT04279847 2026-04-01

LIMBER

Incyte Corporation

Phase 1 Active not recruiting
140 enrolled
Myeloid

Myelodysplastic Syndromes, Myeloproliferative Disorders, Recurrence, Thrombocythemia, Essential, Primary Myelofibrosis

NCT06768476 2026-01-16

AML

University of Pennsylvania

Phase 1 Active not recruiting
12 enrolled
Other hematologic neoplasm

Leukemia, Recurrence, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡